Unaltered intravenous prion disease pathogenesis in the temporary absence of marginal zone B cells

Barry M Bradford1, Neil A Mabbott2

  • 1The Roslin Institute & Royal (Dick) School of Veterinary Sciences, University of Edinburgh, Easter Bush, EH25 9RG, UK.

Scientific Reports
|December 15, 2019
PubMed

Insights

Marginal zone B cells do not transport prions to spleen follicular dendritic cells (FDC) after intravenous exposure. This finding suggests prion delivery to FDC occurs independently of these specialized B cells.

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • Prion diseases are fatal, infectious neurodegenerative disorders affecting humans and animals.
  • Efficient prion infection depends on prion accumulation on follicular dendritic cells (FDC) in B cell follicles after intravenous exposure.
  • The mechanism of prion transport from blood to splenic FDC remains unclear, impacting strategies to reduce prion infection susceptibility.

Purpose of the Study:

  • To investigate the role of marginal zone (MZ) B cells in the initial transport of prions from the bloodstream to splenic FDC.
  • To determine if MZ B cells are essential for prion accumulation on FDC and subsequent host infection following intravenous prion exposure.

Main Methods:

  • Temporary depletion of MZ B cells using antibody-mediated integrin blockade in mice.
  • Intravenous administration of prions to assess prion accumulation on splenic FDC.
  • Evaluation of host susceptibility to prion infection after MZ B cell depletion.

Main Results:

  • Depletion of MZ B cells did not impede the early accumulation of blood-borne prions on splenic FDC.
  • Reduced MZ B cell populations did not alter susceptibility to prion infection after intravenous exposure.
  • These findings indicate that MZ B cells are not critical for the initial delivery of prions to FDC.

Conclusions:

  • The initial transport of blood-borne prions to splenic FDC occurs independently of marginal zone B cells.
  • This study clarifies a key step in prion pathogenesis, suggesting alternative pathways for prion delivery to FDC.